In high-density myoblast cultures S100B enhances basic fibroblast growth factor (bFGF) receptor 1 (FGFR1) signaling via binding to bFGF and blocks its canonical receptor, receptor for advanced glycation end-products (RAGE), thereby stimulating proliferation and inhibiting differentiation. Here we show that upon skeletal muscle injury S100B is released from myofibers with maximum release at day 1 post-injury in coincidence with satellite cell activation and the beginning of the myoblast proliferation phase, and declining release thereafter in coincidence with reduced myoblast proliferation and enhanced differentiation. By contrast, levels of released bFGF are remarkably low at day 1 post-injury, peak around day 5 and decline thereafter. We also show that in low-density myoblast cultures S100B binds RAGE, but not bFGF/FGFR1 thereby simultaneously stimulating proliferation via ERK1/2 and activating the myogenic program via p38 MAPK. Clearance of S100B after a 24-h treatment of low-density myoblasts results in enhanced myotube formation compared with controls as a result of increased cell numbers and activated myogenic program, whereas chronic treatment with S100B results in stimulation of proliferation and inhibition of differentiation due to a switch of the initial low-density culture to a high-density culture. However, at relatively high doses, S100B stimulates the mitogenic bFGF/FGFR1 signaling in low-density myoblasts, provided bFGF is present. We propose that S100B is a danger signal released from injured muscles that participates in skeletal muscle regeneration by activating the promyogenic RAGE or the mitogenic bFGF/FGFR1 depending on its own concentration, the absence or presence of bFGF, and myoblast density.
References
[1]
Chargé SB, Rudnicki MA (2004) Cellular and molecular regulation of muscle regeneration. Physiol Rev 84: 209–238.
[2]
Buckingham M (2006) Myogenic progenitor cells and skeletal myogenesis in vertebrates. Curr Opin Genet Dev 16: 525–532.
Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949–955.
[5]
Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, et al. (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83: 876–886.
[6]
Donato R (2007) RAGE: a single receptor for several ligands and different cellular responses. The case of certain S100 proteins. Curr Mol Med 7: 711–724.
[7]
Arcuri C, Giambanco I, Bianchi R, Donato R (2002) Annexin V, annexin VI, S100A1 and S100B in developing and adult avian skeletal muscles. Neuroscience 109: 371–388.
[8]
Tubaro C, Arcuri C, Giambanco I, Donato R (2010) S100B protein in myoblasts modulates myogenic differentiation via NF-κB-dependent inhibition of MyoD expression. J Cell Physiol 223: 270–282.
[9]
Riuzzi F, Sorci G, Donato R (2011) S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGF-dependent manner. J Cell Sci 124: 2389–2400.
[10]
Sorci G, Agneletti AL, Riuzzi F, Marchetti C, Donato R (2003) S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner. Mol Cell Biol 23: 4870–4881.
[11]
Riuzzi F, Sorci G, Donato R (2006) S100B stimulates myoblast proliferation and inhibits myoblast differentiation by independently stimulating ERK1/2 and inhibiting p38 MAPK. J Cell Physiol 207: 461–470.
[12]
Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R (2004) Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol 24: 4880–4894.
[13]
Riuzzi F, Sorci G, Sagheddu R, Donato R (2011) HMGB1/RAGE regulates muscle satellite cell homeostasis via p38 MAPK/myogenin-dependent repression of Pax7 transcription. J Cell Sci. in press.
[14]
Bianchi ME, Manfredi AA (2007) High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220: 35–46.
[15]
Rauvala H, Rouhiainen A (2007) RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 7: 725–734.
[16]
Riuzzi F, Sorci G, Donato R (2006) The amphoterin/RAGE pair modulates myoblast proliferation, apoptosis, adhesiveness, migration and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 281: 8242–8253.
[17]
Riuzzi F, Sorci G, Donato R (2007) RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 171: 947–961.
[18]
Shi X, Garry DJ (2009) Muscle stem cells in development, regeneration, and disease. Genes Dev 20: 1692–1708.
[19]
Steiner J, Marquardt N, Pauls I, Schiltz K, Rahmoune H, et al. (2011) Human CD8+ T cells and NK cells express and secrete S100B upon stimulation. Brain Behav Immun. doi:10.1016/j.bbi.2011.03.015.
[20]
Charrasse S, Comunale F, Fortier M, Portales-Casamar E, Debant A, et al. (2007) M-cadherin activates Rac1 GTPase through the Rho-GEF trio during myoblast fusion. Mol Biol Cell 18: 1734–1743.
[21]
Zeschnigk M, Kozian D, Kuch C, Schmoll M, Starzinski-Powitz A (1995) Involvement of M-cadherin in terminal differentiation of skeletal muscle cells. J Cell Sci 108: 2973–2981.
[22]
Galbiati F, Volonté D, Engelman JA, Scherer PE, Lisanti MP (1999) Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. J Biol Chem 274: 30315–30321.
[23]
de Angelis L, Zhao J, Andreucci JJ, Olson EN, Cossu G, et al. (2005) Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway. Dev Biol 283: 171–179.
[24]
Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P (2006) Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol 16: 36–44.
[25]
Perdiguero E, Ruiz-Bonilla V, Gresh L, Hui L, Ballestar E, et al. (2007) Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J 26: 1245–1256.
[26]
Serra C, Palacios D, Mozzetta C, Forcales SV, Morantte I, et al. (2007) Functional interdependence at the chromatin level between the MKK6/p38 IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell 28: 200–213.
[27]
Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, et al. (2010) TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7: 455–469.
[28]
Winter B, Arnold HH (2000) Activated Ras kinase inhibits muscle cell differentiation through a MEF2-dependent mechanism. J Cell Sci 113: 4211–4220.
[29]
Lovett FA, Gonzalez I, Salih DA, Cobb LJ, Tripathi G, et al. (2006) Convergence of Igf2 expression and adhesion signalling via RhoA and p38 MAPK enhances myogenic differentiation. J Cell Sci 119: 4828–4840.
[30]
Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164: 441–449.
[31]
De Mori R, Straino S, Di Carlo A, Mangoni A, Pompilio G, et al. (2007) Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol 27: 2377–2383.
[32]
Ma W, Lee SE, Guo J, Qu W, Hudson BI, et al. (2007) RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci 48: 1355–1361.
[33]
Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, et al. (2007) Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 26: 3868–3878.
[34]
S？derberg O, Gullberg M, Jarvius M, Ridderstr？le K, Leuchowius KJ, et al. (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3: 995–1000.
[35]
Bennett AM, Tonks NK (1997) Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 278: 1288–1291.
[36]
Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR (1997) The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272: 6653–6662.
[37]
Jones NC, Tyner KJ, Nibarger L, Stanley HM, Cornelison DD, et al. (2005) The p38alpha/beta MAPK functions as a molecular switch to activate the quiescent satellite cell. J Cell Biol 169: 105–116.
[38]
Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, et al. (2007) The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46: 6957–6970.
[39]
Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, et al. (2008) Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 283: 27255–27269.
[40]
Takaesu G, Kang JS, Bae GU, Yi MJ, Lee CM, et al. (2006) Activation of p38α/β MAPK in myogenesis via binding of the scaffold protein JLP to the cell surface protein Cdo. J Cell Biol 175: 383–388.
[41]
Donato R (1988) Calcium dependent, pH regulated effects of S-100 proteins on assembly-disassembly of brain microtubule protein in vitro. J Biol Chem 263: 106–110.
[42]
Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, et al. (2000) Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through RAGE activation. J Biol Chem 275: 40096–4010.
[43]
Caldwell CJ, Mattey DL, Weller R (1990) Role of the basement membrane in the regeneration of skeletal muscle. Neuropathol Appl Neurobiol 16: 225–238.
[44]
Chen G, Quinn LS (1992) Partial characterization of skeletal myoblast mitogens in mouse crushed muscle extract. J Cell Physiol 153: 563–574.
[45]
Bianchi R, Kastrisianaki E, Giambanco I, Donato R (2011) S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem 286: 7214–7226.
[46]
Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113: 1641–1650.
[47]
Neville C, Rosenthal N, McGrew M, Tsakiris T, Parthimos N, et al. (1997) Skeletal muscle cultures. In Methods in Cell Biology 52: 85–116.
